scholarly journals A randomized, open-label, phase 3 study of nivolumab in combination with ipilimumab vs extreme regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as first-line therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck-CheckMate 651

2016 ◽  
Vol 27 ◽  
pp. vi350 ◽  
Author(s):  
A. Argiris ◽  
M. Gillison ◽  
R.L. Ferris ◽  
K. Harrington ◽  
T.K. Sanchez ◽  
...  
2013 ◽  
Vol 14 (13) ◽  
pp. 1287-1294 ◽  
Author(s):  
Thomas E Hutson ◽  
Vladimir Lesovoy ◽  
Salman Al-Shukri ◽  
Viktor P Stus ◽  
Oleg N Lipatov ◽  
...  

Haematologica ◽  
2022 ◽  
Author(s):  
Carol Moreno ◽  
Richard Greil ◽  
Fatih Demirkan ◽  
Alessandra Tedeschi ◽  
Bertrand Anz ◽  
...  

iLLUMINATE is a randomized, open-label phase 3 study of ibrutinib plus obinutuzumab (n=113) versus chlorambucil plus obinutuzumab (n=116) as first-line therapy for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. Eligible patients were aged ≥65 years, or


Sign in / Sign up

Export Citation Format

Share Document